PTAFR: Platelet-activating factor receptor
Receptor for platelet activating factor, a chemotactic phospholipid mediator that possesses potent inflammatory, smooth-muscle contractile and hypotensive activity.
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on PTAFR, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
| Rupatadine | Approved | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. | Small molecule | AntagonistPlatelet activating factor receptor antagonist | 5 |
| Minopafant ion | Phase 2 | — | Small molecule | AntagonistPlatelet activating factor receptor antagonist | 0 |
| Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients. | Rupatadine | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | Oct 28, 2026 |
| Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis | Rupatadine | Phase 3 | Recruiting | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. | Jul 17, 2026 |
| Rupatadine in Patients With Ulcerative Colitis | Rupatadine | Phase 2 | Recruiting | Alexandria University | Jul 15, 2025 |
| Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants | Rupatadine | Phase 1 | Recruiting | Noucor Health S.A. | Nov 27, 2024 |
| Effect of Some Drugs on Rheumatoid Arithritis Activity | Rupatadine | Phase 3 | Recruiting | Sherief Abd-Elsalam | Dec 10, 2018 |
- Allergic disease0.37
- Cold urticaria0.28
- Chronic idiopathic urticaria0.28
- Rheumatoid arthritis0.26
- Mastocytosis0.18
- Hypothyroidism0.12
- Neoplasm0.11
- Ovarian carcinoma0.11
- Ovarian cancer0.10
- Melanoma0.10
- Chronic obstructive pulmonary disease0.10
- Infection0.09
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL250, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P25105, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets